The trial will assess the safety and tolerability of a single unilateral intracochlear injection. Image: Frank Gärtner/stock.adobe.com. A new clinical trial is evaluating a potential one-time gene therapy for children with GJB2-related hearing loss, the most common genetic cause of inherited paediatric deafness....
Continue reading at Hearing Practitioner Australia
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — this is an early-phase safety trial with no efficacy results yet; audiologists should monitor emerging data but cannot change practice based on current information.
If proven safe and effective, GJB2-targeted gene therapy could offer the first biological cure for the most prevalent form of inherited childhood deafness, fundamentally reshaping paediatric audiology pathways.
- 01Trial targets GJB2-related hearing loss, the most common genetic cause of inherited deafness in children.
- 02Intervention is a single, one-sided (unilateral) injection of gene therapy directly into the cochlea (inner ear).
- 03Primary focus is safety and tolerability — efficacy endpoints are not yet reported.
- 04This is an active clinical trial; results are pending.
- 05GJB2 mutations account for a substantial proportion of congenital genetic hearing loss worldwide.
GJB2-related hearing loss is the most common genetic cause of inherited paediatric deafness.
guidelinesupportedA single unilateral intracochlear gene therapy injection is being evaluated for safety and tolerability in children with GJB2-related hearing loss.
studypartially supported- Publication type
- clinical_trial
- Evidence level
- 1b
- Population
- Children with GJB2-related bilateral sensorineural hearing loss
- Intervention
- Single unilateral intracochlear gene therapy injection targeting GJB2 mutation
Primary outcomes
Safety of intracochlear gene therapy injection; Tolerability of intracochlear gene therapy injection